A first-in-class payload for your next wave of ADCs.
Boehringer Ingelheim is scaling oncology fast — the AimedBio ADC license, the Zai Lab DLL3 collaboration. In ADCs and PDCs, the payload is where differentiation is won. Meet SnB: our proprietary, light-activated DNA-metal payload that plugs into your antibodies and peptides.
Your antibodies. Our payload. One shared platform.
You're assembling an ADC portfolio through targeted deals. GenLumina adds the missing layer — a differentiated payload that isn't tied to a single target. SnB conjugates to any antibody (ADC) or peptide (PDC), so one chemistry breakthrough scales across your pipeline: from HER2 and EpCAM validated today, to DLL3 and solid-tumour targets next. Designed to overcome payload resistance while sparing healthy cells — a wider therapeutic window for the assets you're already building.
Start small. Scale on evidence.
Pick the entry point that fits your process — each one is designed to de-risk the next.
Send us an antibody
We conjugate your validated antibody to SnB and run a proof-of-concept study at no cost to you. No payload chemistry to solve, no upfront commitment.
Option-based Joint Venture per target
Target-by-target co-development on selected indications — the deal structure you already use — with GenLumina's platform, data and IP behind it.
Preferred position
Take a preferred stake in our €5M IND-enabling round for first access to the platform as it moves toward the clinic.
Send us your antibody. We run the proof of concept — on us.
We are the “D” in ADCs and PDCs. We conjugate a validated antibody to SnB and prove the potential for your indication. No payload chemistry to solve. No upfront cost.
Let's find the first target together.
A short intro with the GenLumina team to pick one Boehringer Ingelheim antibody and scope a proof of concept.